A NEW antibiotic developed in Australia, Ramizol, the first of an entirely new class of drug, styrylbenzene antibiotics, has been shown to be effective against 100 different samples of Clostridium difficile, often the cause of hospital iatrogenic drug-resistant infections.
CLICK HERE to access the study.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jun 18
